Archives     Advertise     Editorial Calendar      Advertiser Index     Subscribe     Contact Us    

Aegis Sciences Corporation and Walgreens announce expansion of COVID-19 diagnostic testing


Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative medication compliance testing and consulting services to providers, and Walgreens announced an expansion of their arrangement for the performance of fast and accurate COVID-19 diagnostic testing as Walgreens further expands COVID-19 drive-thru testing nationwide. Together, the companies are in the process of substantially increasing their testing services to provide additional testing capacity with best-in-class turnaround times across more than 3,000 Walgreens pharmacy locations in February. In the coming months, additional growth plans are anticipated.

"Aegis Sciences and Walgreens share a common goal: to provide nationwide access to fast and accurate COVID-19 testing. Aegis's Real Time RT-PCR testing is the diagnostic gold standard with turnaround time of less than 24 hours," said Dr. Frank Basile, Chief Executive Officer, Aegis Sciences Corporation. "We are excited to continue expanding our relationship over the coming months, offering this needed testing in more Walgreens locations and providing more Walgreens customers access to fast and accurate COVID-19 testing."

"The expanded collaboration between Aegis Sciences and Walgreens further builds on our commitment to improve access to COVID-19 testing in the communities we serve," said Rick Gates, Senior Vice President, Pharmacy at Walgreens. "With vaccine inventory still very limited, testing remains one of the best defenses against COVID-19 and the opportunity to stop further community spread."

Since launching COVID-19 testing on April 15, 2020, Aegis has quickly increased testing capacity to meet the needs of communities across the United States. Early last fall, Aegis was selected to participate in the National Institutes of Health Rapid Acceleration of Diagnostics (RADx) initiative and received an NIH grant to expand COVID-19 testing capacity to 60,000 tests per day by September 30, 2020. Since then, Aegis has further increased capacity and is currently able to perform over 100,000 tests per day within a targeted 24-hour or less turnaround time. In January 2021, Aegis was awarded an additional NIH grant due to the success in rapidly expanding its testing program, while maintaining its industry leading turnaround time.

Since launching COVID-19 testing in April 2020, Aegis has performed over 3 million COVID-19 tests. Aegis is constantly working to expedite its testing results, which typically report in 24 hours or less after receipt in the lab, and transparently displays its turnaround time on its website at Aegis is authorized to perform testing and provides all required public health reporting in all 50 states.


Related Articles:

Recent Articles

Ascension Saint Thomas Heart First in State, Region, Ascension to Offer Novel Medical Technique

On February 9, Ascension Saint Thomas Hospital West became the first Ascension hospital in the country and the only medical facility in Tennessee to offer intracoronary brachytherapy, a procedure that helps improve chest pain in patients with stents that have re-narrowed (sometimes called "collapsed") and reduces the chance of them narrowing again in the future.

Read More

Functional Seizures Associated with Stroke, Psychiatric Disorders in Electronic Health Records Study

In a large-scale study of electronic health records, Vanderbilt University Medical Center investigators have determined the prevalence of functional seizures and characterized comorbidities associated with them.

Read More

New survey shows minorities, children missing cancer screenings and vaccinations

52% of adults missing lifesaving screenings to prevent cancer are not rescheduling them

Read More

Sarah Cannon Cancer Institute at Swedish Medical Center Sheds New Light on Brain Tumors

Neurosurgery is a complex and intricate process, and it is important to continuously refine and seek innovative techniques to make it safer, gentler and more precise and effective.

Read More

Study Finds Recommended ICU Sedatives Equally Safe, Effective

Sedative medications used in intensive care are associated with increased delirium, which is in turn connected with higher medical costs and greater risk of death and ICU-related dementia.

Read More

Spectrum Solutions Collaborates with UCLA on Saliva-Based Next-Gen Sequencing (NGS) Liquid Biopsy Research for the Early Detection of Lung Cancer

Study to focus on using saliva in the analysis of cell-free circulating tumor DNA (ctDNA) to accurately and non-invasively detect non-small cell lung cancer (NSCLC).

Read More


Yesterday, counsel for the American Hospital Association and the five other national groups and three individual hospital systems that sued the Department of Health and Human Services (HHS) over its failure to halt drug company actions that undermine the 340B drug pricing program sent letters demanding that the offending drug companies immediately halt their illegal activities.

Read More

Study Shows Drastic Increases in Opioid-Affected Births

The rate of mothers who had an opioid-related diagnosis when delivering their baby increased by 131% from 2010-2017, as the incidence of babies diagnosed with drug withdrawal, known as neonatal abstinence syndrome (NAS), increased by 82% nationally during that same time period.

Read More

Case Management: Enhancing Revenue, Care Transitions and Patient Outcomes throughout the Hospital System

The importance of hospital and health system case management has grown exponentially over the past 10 years and is now getting attention from leaders throughout the healthcare industry.

Read More

TennCare Block Grant Waiver Approved

More than a year after submitting Amendment 42 to the Centers for Medicare and Medicaid Services (CMS) requesting a waiver to increase flexibility in the administration of the state's Medicaid program, Tennessee has received an affirmative nod to move forward.

Read More

Email Print



Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: